Related Experiment Video
Updated: Feb 26, 2026

Impedance-based Real-time Measurement of Cancer Cell Migration and Invasion
Published on: April 2, 2020
CRMP2 inhibits metastasis formation by impairing ILF3-dependent stabilization of CXCL10 mRNA in breast cancer
Binyan Lin1,2, Mei Luo2, Yanqing Zhou3
1State Key Laboratory on Technologies for Chinese Medicine Pharmaceutical Process Control and Intelligent Manufacture, Nanjing University of Chinese Medicine, Nanjing, China.
Abstract:
Tumor-derived elements contribute to the formation of the pre-metastatic niche (PMN) and facilitate cancer metastasis, but much less is known about the key molecular mechanisms. Here, we demonstrate that collapsin response mediator protein 2 (CRMP2), a critical regulator of the cytoskeleton, is associated with metastasis in breast cancer. CRMP2 overexpression inhibits both lung metastasis and PMN formation in breast cancer. Mechanistically, CRMP2 overexpression leads to downregulation of CXCL10. We also found that the correlation between CRMP2 and CXCL10 is mediated by interleukin enhancer-binding factor 3 (ILF3). The D-hydantoinases (D-HYD) fragment of CRMP2 specifically interacts with the second double-stranded RNA binding motif (dsRBM2) of ILF3. Overexpressed CRMP2 reduces the expression of ILF3 in proteasome-dependent degradation via Lys 48-linked polyubiquitination at Lys257, Lys332 and Lys413. In addition, ILF3 directly binds to CXCL10 mRNA, thereby increasing CXCL10 mRNA stability. Finally, we found that psoralen interacts with CRMP2 and suppresses the development of lung metastases in breast cancer. In conclusion, our findings uncover a critical CRMP2-related mechanism behind breast tumor metastasis, and the CRMP2-ILF3-CXCL10 axis may provide a potential therapeutic strategy for controlling breast cancer metastasis.
Insights
Collapsin response mediator protein 2 (CRMP2) inhibits breast cancer metastasis by downregulating CXCL10 via the ILF3 pathway. Psoralen targeting CRMP2 may offer a therapeutic strategy for breast cancer.
Area of Science:
- Oncology
- Molecular Biology
- Cell Biology
Background:
- Tumor-derived factors influence pre-metastatic niche (PMN) formation and cancer spread.
- Key molecular mechanisms driving metastasis remain incompletely understood.
Purpose of the Study:
- Investigate the role of collapsin response mediator protein 2 (CRMP2) in breast cancer metastasis.
- Elucidate the molecular mechanisms by which CRMP2 affects metastasis and PMN formation.
Main Methods:
- Assessed CRMP2 expression in breast cancer.
- Utilized molecular biology techniques to study CRMP2-ILF3-CXCL10 interactions.
- Investigated the effect of psoralen on metastasis in preclinical models.
Main Results:
- CRMP2 overexpression suppressed lung metastasis and PMN formation in breast cancer.
- CRMP2 overexpression led to CXCL10 downregulation, mediated by ILF3.
- CRMP2 induced proteasomal degradation of ILF3, which stabilizes CXCL10 mRNA.
- Psoralen treatment inhibited lung metastasis by interacting with CRMP2.
Conclusions:
- CRMP2 plays a critical role in regulating breast cancer metastasis.
- The CRMP2-ILF3-CXCL10 signaling axis represents a novel mechanism in breast cancer progression.
- Targeting the CRMP2-ILF3-CXCL10 pathway, potentially with agents like psoralen, offers a promising therapeutic avenue for breast cancer metastasis.
Related Concept Videos
MicroRNAs
MicroRNAs
Metastasis
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Abnormal Proliferation

